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LETTERS TO THE EDITOR
Announcement of Protocol Change in
Thrombolysis in Myocardial Infarction Trial
The National Heart. Lung. and Blood Institute' s Thrombolysis in
Myocardial Infarction (TIMO Study has reduced the dose of tissue
plasminogen activator (rt-PA) used from 150 mg over 6 hours to
100 mg over 6 hours. This protocol change was taken after review
and recommendation by an independent Safety and Data Moni-
toring Committee. This recommendation was based in large part
on the occurrence of intracerebral hemorrhage in 5 of 311 patients
(1.6%) during a prerandomization pilot study. Three of these five
events occurred within 24 hours of onset of treatment and three
were fatal during hospitalization. Major hemorrhagic events de-
fined as either intracerebral hemorrhage or a decline in hemoglobin
of ""5 g/dl were observed in 41 of 311 patients (13.2%), However,
the overall in-hospital mortality in this series was 15of 311 (4.8%),
Intracerebral hemorrhage occurred in only I of 386 patients
treated with rt-PA in prior TIMI protocols. All TIMI patients
received full dose heparin anticoagulation in addition to rt-PA
infusion. The etiology of these intracerebral hemorrhages could
be related to multiple factors including prior neurologic disease.
Thrombolytic therapy should be given to individuals only after
careful screening for contraindications such as prior neurologic
events. serious hypertension and potential bleeding sites.
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Genentech Experience With rt-PA (Activase)
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recommendation that thrombolytic therapy should be initiated only
after careful screening for known risk factors.
Table 1
Production Total Dose No. No. Incidence
Process (rug) Treated ICH (%)
Small scale* 40 to 80 341 0 0
Large scale 80 to 119 251 I 0.4
Large scale 120 to 170 406 2 0.5
Total 998 3 0.3
*The small scale process produced the rt-PA used inTIMI phase I and
the dose of 40 to 80 mg was clinically equivalent to a dose of 80 to 100
mg of the large scale rt-PA which was used in the TIMI open label A
through E. ICH = intracerebral hemorrhage.
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Balloon Selection for Double
Balloon Valvotomy
The recent article by Radtkeet al. ( I) describing balloon valvotomy
using oversized balloons proposes the use of an "effective dilation
diameter" for the double balloon technique. The calculations equate
the area of the "oval" enveloping the two balloons with a hy-
pothetical single balloon of larger diameter. It would seem more
appropriate to recognize that. whereas the perimeter of the pul-
monary valve anulus is relatively fixed, the cross-sectional area is
not. Balloon selection should therefore be based on an equivalent
perimeter (Penv), which would result in a somewhat different for-
mula. Using the nomenclature proposed by Radtke (Fig. 6 in Ref.
IJ. the "effective dilation diameter" (den) would equal
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Table I. Effective Dilation Diameter for
Various Dilation Balloon Combinations
In the light of the observations reported by the investigators of the
TIMI trialof the National Heart. Lung. and BloodInstitute (NHLBI).
we have reviewed our experience with the use of rt-PA in myo-
cardial infarction with specific reference to the incidence of intra-
cerebral hemorrhage in the 48 hours after infusion of rt-PA. This
experience includes studies conducted in Europe as well as those
conducted in the United States. exclusive of the NHLBI TIMI trial
(Table 1).
The overall incidence of intracerebral bleeding was 0.3% (3 of
998 patients) with one fatality. Over 400 patients have been treated
at a dose (120 to 170 mg) and duration (3 to 8 hours) comparable
with the regimen used in TIMI open label E and only 2 had
intracerebral bleeding (0.5%). We nevertheless agree with the
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Balloon Diameter (rnrn)
12 15 18 20
19.6 22.1 248 26.5
22.1 24.6 27.1 28.8
24.8 27.1 29.5 31.1
26.5 28.8 31. J 32.7
